Jarden Remains a Buy on CSL (CMXHF)

In a report released on October 13, Steven Wheen from Jarden maintained a Buy rating on CSL, with a price target of A$298.13. The company’s shares closed yesterday at $131.65.

Elevate Your Investing Strategy:

• Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Wheen covers the Healthcare sector, focusing on stocks such as Telix Pharmaceuticals, Regis Healthcare Ltd., and Ramsay Health Care. According to TipRanks, Wheen has an average return of 13.0% and a 51.89% success rate on recommended stocks.

In addition to Jarden, CSL also received a Buy from UBS’s Marcus Curley in a report issued yesterday. However, today, Bell Potter maintained a Hold rating on CSL (Other OTC: CMXHF).

Based on CSL’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $8.21 billion and a net profit of $2.01 billion. In comparison, last year the company earned a revenue of $8.36 billion and had a net profit of $2.91 billion

Based on the recent corporate insider activity of 18 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of CMXHF in relation to earlier this year.